Akebia Ther (AKBA) Stock Analysis

Akebia Ther (AKBA) is a publicly traded company in the HEALTHCARE sector. It trades at $0.94, carries a market capitalization of $273.62M. This page summarizes the public market data, fundamentals, and frequently asked questions for AKBA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Akebia Ther currently has a Neutral sentiment score of 0.09.

About Akebia Ther

Akebia Therapeutics, Inc. (AKBA), based in Cambridge, Massachusetts, is a biopharmaceutical leader focused on developing and commercializing innovative therapies for chronic kidney disease. The company has a strong pipeline that targets significant unmet medical needs in renal care, leveraging advanced research and strategic partnerships to deliver effective treatment solutions. With its commitment to improving patient outcomes, Akebia is well-positioned to make a substantial impact in the ev...

GNG Research Analysis

GNG Research scores Akebia Ther (AKBA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for AKBA.

Frequently Asked Questions

Does AKBA pay dividends?

Akebia Ther (AKBA) does not currently pay a regular dividend.

What is AKBA's market cap?

Akebia Ther (AKBA) has a market capitalization of $273.62M with a current stock price of $0.94.